Dame Kate Bingham served as the Chair of the UK Vaccine Taskforce, on a seven-month unpaid secondment, steering a team of experts to deliver the world's fastest Covid-19 vaccination programme.

She is Managing Partner at life sciences venture capital firm SV Health Investors where she co-leads SV's biotech franchise which has a long history of developing transformational new medicines. SV's investments have led to the launch of twenty drugs for inflammatory and autoimmune disease, blindness and cancer.

At SV, Kate co-manages a number of global biotech venture funds which make investments into innovative companies developing novel therapeutics and she helped launch the Dementia Discovery Fund. She is a board member of the Francis Crick Institute and was awarded a DBE in the Queen's Birthday Honours for her services as Chair of the UK Vaccine Taskforce.

The author proceeds will be donated to the new university The New Model Institute for Technology and Engineering (NMITE) and early years education, development and advocacy charity Kindred Squared.